It also includes Ayvakit/Ayvakyt (avapritinib), a treatment for rare immunological diseases that has received approval in both the US and the European Union. The acquisition also covers elenestinib, a ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

The targeted cancer drug specialist has sold its interest in tyrosine kinase inhibitor Ayvakit/Ayvakyt (avapritinib) and Roche-partnered RET inhibitor Gavreto (pralsetinib) in two separate ...

Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and immunotherapies.